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Background: In order to shed light on the regenerative mechanism of mesenchymal stem cells (MSCs) in vivo,
the bio-distribution profile of implanted cells using a stable and long-term tracking method is needed. We herein
investigated the bio-distribution of human placental deciduas basalis derived MSCs (termed as PDB-MSCs) in
nude mice after intravenous injection by carbon radioisotope labeling thymidine (14C-TdR), which is able to
incorporate into new DNA strands during cell replication.
Results: The proliferation rate and radioactive emission of human PDB-MSCs after labeled with different concentrations
of 14C-TdR were measured. PDB-MSCs labeled with 1 μCi possessed high radioactivity, and the biological characteristics
(i.e. morphology, colony forming ability, differentiation capabilities, karyotype and cell cycle) showed no significant
changes after labeling. Thus, 1 μCi was the optimal concentration in this experimental design. In nude mice, 1 × 106
14C-TdR-labeled PDB-MSCs were injected intravenously and the organs were collected at days 1, 2, 3, 5, 30 and 180 after
injection, respectively. Radiolabeled PDB-MSCs were found mainly in the lung, liver, spleen, stomach and left femur of
the recipient nude mice at the whole observation period.
Conclusions: This work provided solid evidence that 14C-TdR labeling did not alter the biological characteristics of
human placental MSCs, and that this labeling method has potential to decrease the signal from non-infused or dead
cells for cell tracking. Therefore, this labeling technique can be utilized to quantify the infused cells after long-term
follow-up in pre-clinical studies.Background
Mesenchymal stem cells (MSCs) have been regarded as a
promising candidate for cell therapy with increasing evi-
dence of improved therapeutic effectiveness in various dis-
eases [1, 2]. However, the fate and the role of MSCs in
disease progression and regression remain largely unclear.
In vivo tracking of implanted MSCs will provide a power-
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creativecommons.org/publicdomain/zero/1.0/mechanism; especially, the survival, migration and differ-
entiation of MSCs are crucial for successful regeneration.
Thus, reliable and quantitative tracking methods to moni-
tor the in vivo bio-distribution of MSCs are highly desir-
able in animal studies.
Many methods for stem cells tracking are available
currently, such as histological detection of xenogeneic or
chemical-labeled cells, magnetic resonance imaging
scans (MRI), quantum dots (QDs) using fluorescent
semiconductor nanocrystals, ultrasound and radiolabel-
ing by nuclear medicine technology [3–8]. Most of them
are capable of real-time observation and noninvasive,
but the observation time is restricted owing to quick sig-
nal strength decline, limiting the accuracy and reliability
of experimental results.
Radiolabeled thymidine, such as tritiated thymidine
(3H-TdR) and 14C-TdR, can be taken up by thee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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analysis to measure the cell proportion at S phase. Due
to the long half-life (12.35 years) and high radioactivity,
3H-TdR has been used to detect the dynamic distribu-
tion of MSCs [9]. Similarly, 14C has a prominent long
half-life (about 5730 years) which guarantees the long-
term and stably radioactive signal for in vivo detection.
Additionally, thymidine labeling in the 2-carbon pos-
ition can directly degrade into labeled CO2 rather than
labeled β-aminoisobutyric acid or other subsequent me-
tabolites which might be absorbed by the host cells,
thus disturbing the accuracy of detection [10–13].
Hence, these advantages of 14C-TdR ensure its potential
application in cell tracking to aid in long-term observa-
tion after stem cells grafting.
Human placenta-derived MSCs, similar to those from
other sources, possess in vitro differentiation and im-
munomodulatory capacities [14]. Moreover, when trans-
planted in preclinical models, placenta-derived MSCs
show mostly anti-inflammatory and anti-fibrotic effects
[15]. In previous study, we have successfully isolated
MSCs form the deciduas basalis of placenta (termed as
PDB-MSCs) [16]. In order to test the feasibility of 14C
labeled thymidine as the potential tracker for MSCs track-
ing and to investigate the bio-distribution of PDB-MSCs
after implantation, PDB-MSCs was labeled with 14C-TdR
and then injected into the nude mice via the caudal vein
for bio-distribution study.
Results
Determination of the optimal 14C-TdR labeling
concentration for PDB-MSCs
To determine the optimal concentration, the labeling
efficiency of different concentrations of 14C-TdR was an-
alyzed after incubation with PDB-MSCs for 72 h. As
shown in Fig. 1a, the uptake of 14C-TdR, represented as
disintegrations per minute (dpm) per cell, increased in a
dose-dependent manner; unlabeled, 0.2, 1 and 5 μCi-la-
beled groups resulted in 0, 0.0481 ± 0.006, 0.131 ± 0.009
and 0.217 ± 0.015 dpm/cell, respectively (Fig. 1a). How-
ever, increasing concentrations of 14C-TdR administra-
tion were associated with the decreasing of total uptake
efficiency (determined as the percentage of absorbed
14C-TdR versus total treatment dose) of PDB-MSCs be-
cause of limited absorption ability; 0.2 μCi, 1 μCi and
5 μCi treated groups resulted in 21.7 ± 2.88 %, 9.45 ±
0.66 % and 2.75 ± 0.19 % uptake, respectively (Fig. 1b).
Moreover, the effect of different concentrations of 14C-
TdR on PDB-MSCs proliferation was investigated and
CCK-8 was used to assess cell growth rate. As shown in
Fig. 1c, there was no statistical difference in the growth
rate between the control group and those labeled with
0.2 and 1 μCi from day 3 to day 7 (P > 0.05 vs. control).
However, a significant inhibition of proliferation wasrecorded in the group labeled with 5 μCi with the lowest
growth rate during the 7-day period (P < 0.01 vs. con-
trol). These findings suggested that radiotoxicity oc-
curred when the dose was higher than 1 μCi.
Hence, considering the long-term safety and labeling
sensitivity, even though both 0.2 μCi and 1 μCi did not
inhibit the cellular proliferation, 1 μCi was the optimal
concentration for PDB-MSCs labeling owing to its
higher radioactivity (0.131 ± 0.009 dpm/cell). This con-
centration would increase the signal intensity during
detection and thus was used in the subsequent
experiments.
Biological characteristics of 14C-TdR-labeled PDB-MSCs
In order to understand the effects of 14C-TdR labeling
on the biological characteristics of PDB-MSCs, the
morphology, differentiation, colony-forming abilities,
karyotype, and cell cycle were analyzed.
As shown in Fig. 2a, PDB-MSCs labeled with 1 μCi
displayed a similar fibroblastic and spindle-shaped
morphology, similar to that of unlabeled PDB-MSCs.
After culture with specific induction medium, labeled
PDB-MSCs were positive for Alizarin Red and Oil Red
O, respectively, while those cultured in regular medium
were negative (Fig. 2b). Additionally, there was not sig-
nificant difference in the numbers of colony forming
units (CFU) between the labeled and unlabeled groups:
the number of unlabeled group was 583 ± 32.5 and that
of the labeled group was 557 ± 20.1 (Fig. 2c&d). After
cell cycle analysis (Fig. 2e), it was found that both of la-
beled and unlabeled PDB-MSCs displayed the highest
percentage in G0/G1 phase without significant alteration
(labeled group 74.67 %, unlabeled group 76.33 %). Fur-
thermore, 1 μCi 14C-TdR labeling did not change the
karyotype of PDB-MSCs (Fig. 2f ). Thus, the above data
indicated that there was no obvious change in PDB-
MSCs after 1 μCi 14C-TdR labeling.
Bio-distribution of PDB-MSCs in nude mice
At days 1, 2, 3, 5, 30 and 180 post injection, the radio-
activity of each organ was measured following decay and
background corrections, and data were represented as
mean dpm/mg ± standard deviation (SD). At day 1 after
injection, radioactivity was highest in the lung (76.7 ±
31.9 dpm/mg) and it was detectable in the kidney,
spleen, left femur and bone marrow (Fig. 3a); but it was
not detected in the organs from the control group
(radioactivities of the organs from control group had no
significant difference with the background radioactivity).
And the radioactivity in liver and stomach were noted at
day 2 after injection.
The radioactivity of the kidney, spleen and lung were
diminished with time and the signal in the kidney was
disappeared on day 3. Dramatically, cell detection in the
Fig. 1 Optimization of 14C-TdR labeling concentration for PDB-MSCs. a In vitro cellular uptake of 14C-TdR in three different concentrations (0.2, 1 and
5μCi). Disintegration per minute (dpm) per cell was used to express the radioactivity. The radioactivity per cell increased in a concentration-dependent
manner (n = 5). The radioactivity per cell increased in a concentration-dependent manner (n = 5). b 14C-TdR percentage uptake decreased with the
concentration (n = 5). **P < 0.01 compared with the 0.2μCi group; ΔΔP < 0.01 compared with the 1 μCi group. c The proliferation curve of the 4th
passage of PDB-MSCs: 5μCi 14C-TdR labeled PDB-MSCs group showed a lower growth rate than any other groups. One μCi and 0.2μCi groups had the
similar proliferation ability compared to the unlabeled group (n = 6). Data is shown as mean ± SD, N = 5 for 14C-TdR labeling study, N = 6 for cell
proliferation analysis. **P < 0.01 1 μCi group compared with the control group; ##P < 0.01 0.2μCi group compared with the control group; ΔΔP < 0.01
5μCi group compared with the control group
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to 7.64 ± 1.59 dpm/mg) (Fig. 3a). Beyond a decline on
day 2, a stable radioactivity was observed in the left
femur and bone marrow which was even peaked on day
30 (5.47 ± 0.314 dpm/mg) (Fig. 3a). The radioactivity
value of liver increased from 2.05 ± 0.257 dpm/mg (day 2)
to 5.31 ± 1.337 dpm/mg on day 3; and then it decreased
gradually to 0.99 ± 0.027 dpm/mg on day 30. Similarly,
radioactivity value of stomach experienced a rise from
3.55 ± 0.797 dpm/mg (day 2) to 5.74 ± 0.058 dpm/mg on
day 3 and dropped to 1.41 ± 0.102 dpm/mg on day 30
(Fig. 3a). No radioactivity was found in the heart, blood,
brain and left femur muscle (Fig. 3a).
The number of infused cells in each organ on day 30
was calculated according to average radioactivity of in-
fused cells. As shown in Fig. 3b, the left femur harvested
with bone marrow had the highest number of infusedPDB-MSCs per gram (41,725 ± 2394/g) and the number
of cells in lung, spleen, stomach, and liver detected on
day 30 were 32,748 ± 3586, 16,031 ± 5640, 10,763 ± 777,
7557 ± 207 per gram of tissue, respectively. As two mice
died because of the feeding machine accident, only one
mouse was used for organs collection on day 180. The
radioactivity in the organs were mainly detected in liver
(1.08 dpm/mg), lung (3.82 dpm/mg) and left femur har-
vested with bone marrow (5.31 dpm/mg), indicating that
the infused PDB-MSCs were able to exist in bone tissue
up to 6 months (Fig. 3a).
Immunohistochemistry results
Anti-human mitochondria antibody was used to detect the
PDB-MSCs in the organs of nude mice. As shown in Fig. 4,
negative result was found in control group (Fig. 4 a-e); at
day 2 after injection, human cells were found in bone
Fig. 2 Analysis of biological characteristics of PDB-MSCs after labeling. a The 4th passage of PDB-MSCs showed similar fibroblast-like morphology
after cultivation in standard culture medium with and without 1 μCi 14C-TdR for 72h. Scale bar = 200μm. Differentiation capability of 1 μCi 14C-
TdR labeled and unlabeled PDB-MSCs (b). Alizarin Red staining of differentiated (day 21) and control cells for osteogenic differentiation study,
scale bar = 500μm. Oil red O staining of differentiated (day 8) and control cells for adipogenic differentiation study, scale bar =100μm. The CFU
potential of 1 μCi 14C-TdR labeled and unlabeled PDB-MSCs at 8 days (c and d). Crystal violet (0.1 %) staining of 1 μCi 14C-TdR labeled (557 ± 20.1)
and unlabeled (583 ± 32.5) PDB-MSCs shows no significant difference in colony-forming ability (n = 4) (P > 0.05). The 4th passage PDB-MSCs
stained with PI were prepared for cell cycle analysis by NovoCyte flow cytometer and data were analyzed by NovoExpress analysis software. 1 μCi
14C-TdR labeled PDB-MSCs and unlabeled PDB-MSCs showed the similar trend and proportion of G0/G1, S and G2-M phase (e). Chromosome
spread and karyotypic analysis of 1 μCi 14C-TdR labeled 4th passage PDB-MSCs (f). 22 pairs of somatic chromosomes were shown, as well as two
X chromosomes, for a total of 46 chromosomes. Data were expressed as mean ± SD, N = 4 for CFU experiments
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dent with the radioactivity analysis results (Fig. 4 f-j). Posi-
tive staining was only found in bone marrow, lung and liver
on day 30 (Fig. 4 k-o). Thus, the same bio-distribution
trend of PDB-MSCs in nude mice via IV injection was ob-
tained after radioactivity and immunohistochemistry
analysis.
Discussion
In this study, it was determined that PDB-MSCs labeled
with 1μCi 14C-TdR did not have alterations in biological
characteristics, and that after IV injection in nude mice,human PDB-MSCs were found to be presented in bone
marrow, lung, liver, spleen and stomach.
At present, MRI, scintigraphic tracking, quantum dots
(QDs), reporter gene labeling and optimal imaging, have
been widely used for cell tracking. MRI is the most
widely used due to its safety and the capacity of 3-
dimensional observation [17]. But several drawbacks
were existed [18, 19]. For example, MRI cannot distin-
guish iron-labeled cells from the iron particles; second,
the low sensitivity of MRI in clinical trails should be im-
proved by up-regulating the magnetic field strengths,
however, the toxic effects of MRI contrast agents on
Fig. 3 Bio-distribution and quantitative results of infused 14C-TdR labeled PDB-MSCs. a The bio-distribution of 1 μCi 14C-TdR labeled 4th passage
PDB-MSCs after IV injection in nude mice. 14C radioactivity of each organ was detected by liquid scintillator counter at 6 different time points after
injection (at day 1, day 2, day 3, day 5, day 30 and day 180). b Quantification of infused 14C-labeled PDB-MSCs in different organs of the nude
mice on day 30. The quantity of infused cells is expressed as number per gram which is calculated through the average activity of 1 μCi labeling
PDB-MSCs (0.131dpm/cell) and the radioactivity (dpm/mg) of the organs at day 30 (a). Values were presented as mean ± SD of three
independent experiments
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method for cell tracking is scintigraphy using radio-
labeling materials: 111In-oxine, 64Cu-PTSM and 124I-
FIAU, which can be visualized by positron emission
tomography (PET) or single photon emission computed
tomography (SPECT) and mainly applied in whole-body
bio-distribution analysis [8, 19, 23–29]. This method is
relatively highly sensitive and quantitative, however toxic
effects on cell viability and photon attenuation by tissue
should be considered [25, 30]. Also, QDs and reporter
gene labeling induce cytotoxicity and require genetic
modification or perturbation; additionally, quantification
is difficult to be achieved [18]. Real time PCR (RT-PCR)
is a valid alternative for the detection of human cells
after xenografting, and had been utilized for detecting
MSCs [28, 31–35] in mouse, rabbit and sheep models[33, 36]; but this technique is a little bit complex and is
not efficient enough to pick up small cell numbers from
the large organs.
In this work, 14C-TdR in the culture medium can be
absorbed and incorporated in newly-synthesized DNA
during cell replication, thus making it a stable tracer. As
the aim of our research was to find a long-term, stable
and quantitative method for PDB-MSCs tracking, hence
comparison of the sensitivity of 14C-labeling method
with other tracking methods was not performed, which
should be investigated in future study.
After IV injection for 24 h, radioactivity was mainly
presented in lung, kidney and spleen, which was consist-
ent with the findings from other groups after IV injec-
tion of MSCs [26–28]. It was reported that 99 % of
intravenously injected MSCs were cleared from the
Fig. 4 Immunohistochemical staining of infused human cells. Sections of human mitochondria were analyzed in bone marrow, lung, liver, kidney
and spleen at day 1 (negative control group), day 2 and day 30 after human PDB-MSCs infused. No human cells were found in negative control
group (a-e). At day 2 after 14C-TdR labeled PDB-MSCs infusion, PDB-MSCs were found in bone marrow, lung, liver, kidney and spleen (f-j). After 30
days,PDB-MSCs were found in bone marrow, lung, liver but not kidney and spleen (k-o). Human skin sections were stained as positive control (p).
Scale bar = 100μm
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able that the radioactivity in blood was not noted after 24
h in this study. No PDB-MSCs was found in the brain,
heart and muscle; this result was conflicted with some
previous findings [9, 26, 27, 34, 36] which might be related
to the variety of animal models, sources of MSCs and the
trackers. It was demonstrated that the liver possessed a
large proportion of infused cells [8, 26–29], which was not
observed in our study until 5 days after infusion. The aver-
age diameter of human PDB-MSCs is 20-25μm (data not
shown) and the diameter of capillaries in lungs is approxi-
mate 10 ~ 20μm; therefore, most of the infused cells may
accumulate in the filtering organs such as the lungs, liver
and spleen. Since the lung is considered as the first organ
after IV injection, many literatures suggested that majority
of infused cells were initially trapped into lung for the first24 h [9, 29] or earlier [27–29] after IV injection. Apart
from the lung, bone marrow and spleen were detected
with the highest radioactivity on day 30. The possible ex-
planation was that bone marrow is the major stem cell
niche which might be the preferential migration target for
MSCs. Spleen acts as a blood filter and it is an important
part of immune system which might continuously filter
cell debris or other incomplete catabolism products with
14C, thus increasing its radioactivity. Further studies need
to be done to clarify the migration mechanism of intra-
venously injected MSCs, which is the major limitation in
our study that we should acknowledge.
Conclusion
In summary, PDB-MSCs could be labeled with 1μCi
14C-TdR successfully without significant changes in the
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cell cycle profile; after intravenous injection, most of the
14C-TdR-labeled PDB-MSCs were initially located in the
lung, spleen, stomach, femur and bone marrow and then
the cells were quickly cleared in the first 5 days after in-
jection; a small number of PDB-MSCs were detectable
in liver, lung and left femur at 180 days after injection.
Even though the cell number kept decreasing, this label-
ing method allowed the determination of the cell
number presented at different time points. Therefore,
[2-14C], 14C-TdR may be a stable, long-term and quanti-
tative cell tracker after MSCs implantation.
Methods
Cell isolation and culture
Human placenta samples were obtained from three
healthy donor mothers with written informed consent.
The study has been approved by the ethics committee of
West China Hospital, Sichuan University. PDB-MSCs
were isolated according to our previous report [16].
Briefly, decidua basalis was collected and washed in
phosphate-buffered saline to remove residual blood. The
samples were mechanically minced into small particles,
and digested with 0.25 % trypsin (Gibco, USA) and 0.1 %
collagenase IV (Invitrogen, USA) and 80U/ml DNAse I
(Sigma, USA) for 30 mins at 37°C. Nucleated cells were
concentrated by density gradient centrifugation (500 g
for 30 mins), suspended in 5 ml complete medium con-
taining Dulbecco’s modified Eagle’s medium-High Glu-
cose (DMEM-HG, Gibco, USA) with 10 % v/v fetal
bovine serum (FBS, Hyclone, South America) and 1 %
penicillin/streptomycin, and incubated in a 25 cm2
culture flask at 37 °C with 5 % CO2. After 70–80 % con-
fluence, cells were passaged at a dilution of 1:3. Cells
from the 4th passage were used in the subsequent
assays.
14C-TdR labeling of PDB-MSCs
To determine the optimal labeling condition, 3 × 105
PDB-MSCs were treated with different concentrations of
14C-TdR (PerkinElmer, Boston) (0.2μCi, 1μCi, 5μCi) and
incubated for 72 h at 37°C with 5 % CO2. After incuba-
tion, cells were washed with phosphate buffer saline
(PBS, pH = 7.4) twice and harvested by 0.25 % trypsin/
ethylene diamine tetraacetic acid (EDTA); the radioactiv-
ity of 14C in labeled PDB-MSCs was measured by liquid
scintillator counter (Beckman, USA) to estimate the up-
take of each concentration.
Cell proliferation
Cell proliferation was assessed using CCK-8 Kit
(Dojindo, Japan). Briefly, 2 × 103 PDB-MSCs and 14C-
TdR labeled PDB-MSCs with four concentrations, were
plated in 96-well. Cell viability was monitored on days 0,1, 3, 5 and 7, respectively. One hour after the addition of
10μl CCK-8 in 100μl culture medium optical density
was determined using a spectrophotometer at 490 nm
with background correction at 630 nm.
Cell differentiation
To analyze the effect of 14C-TdR labeling on the multi-
potency of PDB-MSCs, osteogenic and adipogenic differ-
entiation were performed in the unlabeled group and
the 1μCi 14C-TdR labeled group. To induce osteogenic
differentiation, radiolabeled and unlabeled PDB-MSCs
were seeded in 6-well plates at a density of 5 × 103 cells/
well and cultured with osteogenic medium (complete
medium with 10mM β-glycerol phosphate (Sigma,
Switzerland), 0.1μM dexamethasone (Sigma, USA) and
50μg/ml ascorbate-2 (Sigma, USA)) for 21 days. The
medium was changed every 3 days. After induction, cells
were fixed with 75 % ethanol for 20 mins, washed with
PBS twice and stained with Alizarin red solution (Sigma,
USA) for 30 mins.
For adipogenic induction, labeled and unlabeled cells
were plated at a density of 5 × 103 cells/well and induced
in the adipogenic medium consisting of 0.5μM isobutyl-
methylxanthine (Sigma, USA), 0.25μM dexamethasone
(Sigma, USA), 10μM insulin (Sigma, USA) and 50μM
indomethacin (Sigma, Germany). The medium was re-
placed every 3 days. After 8 days, cells were fixed with
10 % formalin and stained for 30 mins with Oil red O
solution (Sigma, USA) to visualize lipid vacuoles.
CFU assay
For the analysis of colony forming ability, labeled and
unlabeled PDB-MSCs were plated at a density of 80
cells/cm2 and cultured in completed medium. After 8
days, cells were washed with PBS, fixed with methanol
for 5 mins and stained with 0.1 % crystal violet (Sigma,
USA) solution for 30 mins at 37 °C. The number of
MSCs clones was counted using the Image-Pro Plus 6.0
software (Media Cybernetics, USA).
Karyotype analysis
For karyotype analysis, 14C-labeled PDB-MSCs were
treated with 10μl/mL colcemid (Gibco, USA) for 2.5 h,
added to 1ml 0.075M KCl solution for 20 mins and then
fixed in 3ml Carnoy fixative for 30 mins at 37 °C. The
cell specimens were made by standard air drying
method. The G-band of labeled PDB-MSCs was ana-
lyzed by Metafer 4 Scanning System and the Ikaros
Karyotype System (MetaSystems, USA).
Cell cycle analysis
For cell cycle analysis, 2 × 106 labeled and unlabeled
PDB-MSCs were suspended in 70 % alcohol and stored
at −4 °C overnight. After centrifugation and washing
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solution containing 50 μg/ml PI (Sigma, USA), 0.1 mg/
ml RNase A (Sigma, UK) and 0.05 % Triton X-100 for
30 mins in the dark at −4 °C. DNA index was measured
by NovoCyte Flow Cytometer (ACEA Biosciences,
China) and data were analyzed by NovoExpress analysis
software (ACEA Biosciences, China).
In vivo infusion and bio-distribution
All animal experiments were approved by the Institutional
Animal Care and Use Committee of Sichuan University,
and were carried out following Committee regulations
and the Principles of Laboratory Animal Care formulated
by the National Society for Medical Research. Four week-
old female BALB/C nude mice (n = 21, purchased from
Chengdu Dashuo Laboratory Animal Limited Company),
used in this study, were randomly divided into 7 groups.
In the experimental groups, each mouse was injected with
approximately 1 × 106 1 μCi 14C-TdR labeled PDB-MSCs
via caudal vein and unlabeled PDB-MSCs served as the
control group.
Mice injected with labeled PDB-MSCs were sacrificed
on days 1, 2, 3, 5, 30 and 180; mice injected with un-
labeled PDB-MSCs were sacrificed on day 1. Organs in-
cluding heart, liver, kidney, stomach, spleen, lung, blood,
brain, left femur muscle, and the bone marrow from left
femur (along with the femur itself ) were harvested. Be-
fore the radioactivity assay, each organ was weighed and
chemically digested with 100μl 30 % H2O2 (Kelong,
Chengdu) and 200μl 60 % perchloric acid (Kelong,
Chengdu) for 30 mins at 80 ~ 90 °C. During sample pro-
cessing, the left femur containing both bone and the
bone marrow was used en bloc since it was difficult to
accurately weigh them. LS 6500 Scintillation Counter
(Beckman, USA) was used to assess the radioactivity of
each organ. Part of liver, lung and spleen, right femur
and right kidney were prepared for immunohistochemi-
cal staining on day 2 and day 30, nude mice injected
with PBS (pH = 7.4) were served as negative control
group.
Immunohistochemistry
For immunohistochemical staining, samples were fixed
with 4 % paraformaldehyde for 48 h at room
temperature. Bone samples were decalcified for 3 weeks
in 10 % EDTA (pH 7.4) with weekly changes, and then
all the samples were embedded in paraffin. Anti-human
mitochondria antibody (1:400; ab92824, Abcam, Cam-
bridge, UK) were used for detecting human cells in nude
mice. After dewaxed and rehydrated, sections(4μm) were
blocked with 3 % hydrogen peroxide for 15–20 mins at
room temperature, followed by incubation with pepsin
solution digest-all (Invitrogen, USA) for 20 mins at room
temperature for bone sections antigen retrieval. Otherorgans sections were placed in trisodium citrate buffer
(pH = 6.0) for 40 mins at 95 °C. After naturally cooled to
room temperature, the sections were washed with PBS
for 3 times and incubated with the primary antibody
solutions overnight at 4 °C. Sections were rinsed with
deionized water and then PBS, followed by 30 mins in-
cubation with horse reddish peroxidase working solution
(Gene Tech, Shanghai) at room temperature for 30 mins.
After washed, 50-100μl 3,3′-diaminobenzidine (DAB)
(Gene Tech, Shanghai) working solution was used for 5–
10 mins at room temperature. The sections were then
lightly counterstained with hematoxylin.
Statistical analysis
All data were expressed as mean ± SD. Statistical analysis
was performed using SPSS17.0 software (SPSS, USA).
Results were analyzed with Student’s T-test and P < 0.05
were considered as statistically significant.
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